Xu Lei, Yang Chung S, Liu Yanan, Zhang Xin
Department of Food Science and Engineering, Ningbo University, Ningbo, China.
Department of Chemical Biology, Ernest Mario School of Pharmacy, Rutgers The State University of New Jersey, Piscataway, NJ, United States.
Front Pharmacol. 2022 Apr 25;13:895193. doi: 10.3389/fphar.2022.895193. eCollection 2022.
Coronavirus disease 2019 (COVID-19) can disrupt the gut microbiota balance, and patients usually have intestinal disorders. The intestine is the largest immune organ of the human body, and gut microbes can affect the immune function of the lungs through the gut-lung axis. Many lines of evidence support the role of beneficial bacteria in enhancing human immunity, preventing pathogen colonization, and thereby reducing the incidence and severity of infection. In this article, we review the possible approach of modulating microbiota to help prevent and treat respiratory tract infections, including COVID-19, and discuss the possibility of using probiotics and prebiotics for this purpose. We also discuss the mechanism by which intestinal micro-flora regulate immunity and the effects of probiotics on the intestinal micro-ecological balance. Based on this understanding, we propose the use of probiotics and prebiotics to modulate gut microbiota for the prevention or alleviation of COVID-19 through the gut-lung axis.
2019冠状病毒病(COVID-19)会破坏肠道微生物群平衡,患者通常会出现肠道紊乱。肠道是人体最大的免疫器官,肠道微生物可通过肠-肺轴影响肺部的免疫功能。许多证据支持有益菌在增强人体免疫力、防止病原体定植从而降低感染发生率和严重程度方面的作用。在本文中,我们综述了调节微生物群以帮助预防和治疗包括COVID-19在内的呼吸道感染的可能方法,并讨论了为此目的使用益生菌和益生元的可能性。我们还讨论了肠道微生物群调节免疫的机制以及益生菌对肠道微生态平衡的影响。基于这一认识,我们建议通过肠-肺轴使用益生菌和益生元来调节肠道微生物群,以预防或减轻COVID-19。